“The company’s strength in bioanalytical and DMPK services has been heavily driven by increasing customer demand for regulatory-compliant solutions over the past two to three years,” said Dr. Jason Liu, SVP of WuXi AppTec, COO of the Laboratory Testing Division.
“The site expansion bolsters WuXi’s Laboratory Testing Division in these services and establishes New Jersey site as a center of excellence in providing IND and NDA enabling services,” he told us.
When fully configured, Liu said the new facility add 55,000 square feet of laboratory space to WuXi AppTec’s Laboratory Testing Division (LTD) as well as more than 200 new jobs.
“This addition expands upon our established Plainsboro facility, offering testing services to pharmaceutical and biotech companies,” he explained.
Additionally, “through the expansion efforts,” Liu said the company will be converting its current Plainsboro laboratory into a fully good laboratory practice (GLP) regulated bioanalytics facility with double the space.
WuXi’s Laboratory Testing Division provides in vivo and in vitro assays from early screening to clinical sample analysis, as well as medical device testing from development to product lifecycle management.